Ameliorative effect of Chlorophytum borivilianum root on lipid metabolism in hyperlipaemic rats.
1. The present study examined the efficacy of Chlorophytum borivilianum root (powder) in modulating the hyperlipaemic/hypercholesteraemic conditions in male albino rats. 2. Administration of C. borivilianum (0.75 and 1.5 g root powder/rat per day for 4 weeks) to hypercholesteraemic rats significantly increased high-density lipoprotein-cholesterol levels and decreased plasma and hepatic lipid profiles. 3. In addition, there were significant increases in faecal cholesterol, neutral sterol and bile acid excretion with elevated hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and bile acid production. 4. Furthermore, the hypercholesteraemic rats treated with both doses of C. borivilianum also exhibited increases in superoxide dismutase and ascorbic acid levels. 5. Normocholesteraemic animals treated with both doses of C. borivilianum root powder did not show any significant variation in either lipid or anti-oxidant profiles, except for an increase in the hepatic ascorbic acid concentration compared with their untreated counterparts. 6. The hypolipaemic/hypocholesteraemic effect of C. borivilianum root powder appears to be mediated by an increase in cholesterol turnover via increased faecal cholesterol excretion and, second, through an endogenous cholesterol conversion into bile acid. 7. Administration of C. borivilianum root powder also increased the activities of anti-oxidant enzymes and vitamin C levels, which may have enhanced the anti-oxidant capacity of the liver.
Visavadiya
N P
NP
Department of Biosciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India.
Narasimhacharya
A V R L
AV
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001205:Ascorbic Acid / Q000378:metabolism; D001647:Bile Acids and Salts / Q000032:analysis / Q000378:metabolism; D002374:Catalase / Q000378:metabolism; D002784:Cholesterol / Q000032:analysis / Q000097:blood; D004032:Diet; D005243:Feces / Q000737:chemistry; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D019668:Liliaceae / Q000737:chemistry*; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010936:Plant Extracts / Q000494:pharmacology; D018517:Plant Roots / Q000737:chemistry; D051381:Rats; D013261:Sterols / Q000032:analysis / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D000975:Antioxidants; D001647:Bile Acids and Salts; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D010936:Plant Extracts; D013261:Sterols; D014280:Triglycerides; D002784:Cholesterol; D002374:Catalase; D013482:Superoxide Dismutase; D001205:Ascorbic Acid